Can Historical Cash Flow
| CANF Stock | USD 1.48 0.06 3.90% |
Analysis of Can Fite cash flow over time is an excellent tool to project Can Fite Biopharma future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 350.5 K or Begin Period Cash Flow of 4.6 M as it is a great indicator of Can Fite ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Can Fite Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Can Fite Biopharma is a good buy for the upcoming year.
Can |
About Can Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Can balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Can's non-liquid assets can be easily converted into cash.
Can Fite Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Can Fite Biopharma to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Can Fite operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Can Fite's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Can Fite Biopharma current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Can Fite's Begin Period Cash Flow is most likely to decrease significantly in the upcoming years. The Can Fite's current Depreciation is estimated to increase to about 18.6 K, while Change In Working Capital is forecasted to increase to (1 M).
| 2022 | 2024 | 2025 (projected) | Dividends Paid | 2.6M | 3.0M | 1.8M | Issuance Of Capital Stock | 6.5M | 10.5M | 12.5M |
Can Fite cash flow statement Correlations
Click cells to compare fundamentals
Can Fite Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Can Fite cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 5.6M | (3.9M) | (1.4M) | 1.3M | 1.2M | 1.2M | |
| Stock Based Compensation | 355K | 398K | 263K | 261K | 300.2K | 350.5K | |
| Free Cash Flow | (12.1M) | (9.9M) | (10.8M) | (8.4M) | (7.6M) | (8.0M) | |
| Change In Working Capital | 2.0M | 2.5M | (1.3M) | (943K) | (1.1M) | (1.0M) | |
| Begin Period Cash Flow | 2.7M | 8.3M | 4.4M | 3.0M | 2.7M | 4.6M | |
| Other Cashflows From Financing Activities | (26K) | 715K | 23.0M | 498K | 572.7K | 544.1K | |
| Other Non Cash Items | 1K | (46K) | 396K | (139K) | (125.1K) | (131.4K) | |
| Capital Expenditures | 26K | 11K | 9K | 2K | 1.8K | 1.7K | |
| Total Cash From Operating Activities | (12.1M) | (9.9M) | (10.8M) | (8.4M) | (7.6M) | (8.0M) | |
| Net Income | (14.4M) | (12.6M) | (10.2M) | (7.6M) | (6.9M) | (7.2M) | |
| Total Cash From Financing Activities | 10.2M | 17.7M | 20.5M | 9.1M | 10.5M | 10.5M | |
| End Period Cash Flow | 8.3M | 4.4M | 3.0M | 4.3M | 3.9M | 4.6M | |
| Total Cashflows From Investing Activities | (3K) | (26K) | (14.5M) | 9.5M | 8.6M | 9.0M | |
| Change To Liabilities | 1.2M | (2.0M) | 1.8M | (868K) | (998.2K) | (948.3K) | |
| Change To Operating Activities | (517K) | (278K) | 694K | (379K) | (435.9K) | (414.1K) | |
| Change To Netincome | 543K | 1.9M | 258K | 605K | 695.8K | 730.5K | |
| Investments | (26K) | (14.5M) | 9.5M | 498K | 572.7K | 601.3K | |
| Issuance Of Capital Stock | 17.7M | 20.5M | 6.5M | 9.1M | 10.5M | 12.5M |
Currently Active Assets on Macroaxis
When determining whether Can Fite Biopharma is a strong investment it is important to analyze Can Fite's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Can Fite's future performance. For an informed investment choice regarding Can Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Can Fite. If investors know Can will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Can Fite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Can Fite Biopharma is measured differently than its book value, which is the value of Can that is recorded on the company's balance sheet. Investors also form their own opinion of Can Fite's value that differs from its market value or its book value, called intrinsic value, which is Can Fite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Can Fite's market value can be influenced by many factors that don't directly affect Can Fite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Can Fite's value and its price as these two are different measures arrived at by different means. Investors typically determine if Can Fite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Can Fite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.